The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Local Delivery of Ox40l , Cd80 , and Cd86 mRNA Kindles Global Anticancer Immunity
Open accessPublished version of a preprint
Abstract
Localized expression of effector molecules can initiate antitumor responses through engagement of specific receptors on target cells in the tumor microenvironment. These locally induced responses may also have a systemic effect, clearing additional tumors throughout the body. In this study, to evoke systemic antitumor responses, we utilized charge-altering releasable transporters (CART) for local intratumoral delivery of mRNA coding for costimulatory and immune-modulating factors. Intratumoral injection of the CART–mRNA complexes resulted in mRNA expression at the site of administration, transfecting a substantial proportion of tumor-infiltrating dendritic cells, macrophages, and T cells in addition to the tumor cells, resulting in a local antitumor effect. Using a two-tumor model, we further show that mRNA therapy locally administered to one tumor stimulated a systemic antitumor response, curing both tumors. The combination of Ox40l-, Cd80-, and Cd86-encoding mRNA resulted in the local upregulation of proinflammatory cytokines, robust local T-cell activation, and migration of immune cells to local draining lymph node or to an anatomically distant tumor. This approach delayed tumor growth, facilitated tumor regression, and cured tumors in both A20 and CT26 tumor models. These results highlight mRNA-CART therapy as a viable approach to induce systemic antitumor immunity from a single localized injection. Significance: The mRNA-CART system is a highly effective delivery platform for delivering immunostimulatory genes into the tumor microenvironment for potential therapeutic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, charge-altering releasable transporters162,247 and modified dendrimers248 can effectively deliver mRNA molecules in vitro and in vivo.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [162]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Toll-like receptors and innate immunity
Medzhitov, R. (2001) · Nature Reviews Immunology · doi:10.1038/35100529 · Cited by 4,308
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,196
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,139
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.14 · Cited by 920
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
Freeman, G. J., Gribben, J. G., Boussiotis, V. A., Ng, J. W., Restivo, V. A., Lombard, L. A., Gray, G. S., & Nadler, L. M. (1993) · Science · doi:10.1126/science.7694363 · Cited by 903
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 806
Cited by
Sorted by citations
Items 101–129 of 129
Hurst, P. J., Jia, Y., Ramsay-Burrough, S., McClellan, R. L., Arens, J. T., Khasnavis, S. R., Castillo, T. J. D., Elwakil, M. M. A., Lueckheide, M. J., Prabhu, V. M., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c07147 · Cited by 2
Self-citationOptimizing C14120-based LNPs for in vitro and in vivo mRNA delivery
Song, P., Su, J., Vraa, C. L. K., Gockert, M., Fjelstrup, S., Hager, H., & Kjems, J. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102866 · Cited by 1
Tumor-Associated Macrophages: Therapeutic Targets of Cancer
Li, Y., Zhang, X., Zeng, X. L., Wang, S., & Wang, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-84164-5_13 · Cited by 1
Nanomedicine: Present Perspectives and Future Challenges
Ali, S., Sadia, A., & Tariq, I. (2023) · Learning materials in biosciences · doi:10.1007/978-981-99-7626-3_1 · Cited by 1
Silicon-based metal-organic frameworks (SiMOFs) for immunogenic cell death in cancer therapy
Han, M. H., Chen, Z., Zhou, S., Liao, Z., Yi, X., He, Y., Zhong, Y., & Leong, K. W. (2024) · Nano Research · doi:10.26599/nr.2025.94907080 · Cited by 1
Industry Updates from the Field of Stem Cell Research and Regenerative Medicine in September 2019
Ilić, D., Liović, M., & Noli, L. (2019) · Regenerative Medicine · doi:10.2217/rme-2019-0131 · Cited by 1
Horozoğlu, C., Sönmez, D., Küçükhüseyin, Ö., Demirkol, Ş., Hakan, M. T., Arıkan, S., & Yaylım, İ. (2021) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2020-0075 · Cited by 1
Delivery strategies for reprogramming tumor-associated macrophages
Ramesh, A., & Kulkarni, A. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00004-x · Cited by 1
Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy
Madkour, L. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819777-6.00021-4
Nucleic acid-based immune checkpoint blockade: Progress and potential
Walters, A. A., Dhadwar, B., & Al‐Jamal, K. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00011-7
Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effect
Ott, P. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.004
Macrophages and their antitumor activity
Zhou, Z. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822368-0.00024-4
Antimetastatic effect of intratumoral Treg antagonists in mice with renal cancer
Gulyás, D., Kovács, G., Jankovics, I., Hídvégi, M., Denes, B. S., Kálfalvy-Molnár, L., Nagypál, R., & Lőrincz, M. (2024) · Acta Veterinaria Hungarica · doi:10.1556/004.2024.01037
Leong, M. L. L., Liu, W., Fay, N. C., Silva, D. M. D., Ou, L., Rae, C. S., Sallets, A., Prins, R., Frimannsson, D. O., McKinlay, C. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.24.678202
Self-citationJia, W., Luo, S., Gena, L., Li, S., Huo, S., Li, M., & Zeng, X. (2021) · Figshare · doi:10.6084/m9.figshare.14676967
Jia, W., Luo, S., Gena, L., Li, S., Huo, S., Li, M., & Zeng, X. (2021) · Figshare · doi:10.6084/m9.figshare.14676973
Jia, W., Luo, S., Gena, L., Li, S., Huo, S., Li, M., & Zeng, X. (2021) · Figshare · doi:10.6084/m9.figshare.14676970
Han, Y., Gao, X., Dong, J., Jiang, M., Xin, N., Chen, X., Li, Z., & Li, Y. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.173282
mRNA Technology Beyond Vaccines: Exploring Potential mRNA-Based Therapies for Autoimmune Diseases
Kharat, M. G., Kulkarni, V. A., Chavan, S. P., Gawali, N. B., & Khandarkar, S. M. (2026) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2026.00001
Naghib, S. M., Kashani, G. K., Shamaeizadeh, A., & Mahdavi, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-31490-2.00008-3
Linares-Fernández, S. (2021) · theses.fr (ABES) · doi:10.70675/17ec09cezeb11z45f7z8529z7ffbf89d664a
Reprogramming tumor-associated macrophages using siRNA-loaded lipid nanoparticles
Gul, S. (2025) · theses.fr (ABES) · doi:10.70675/a1043f82z871dz417ezb779z6fa27df750ce
Ishikawa, U., Mabrouk, M. T., & Yang, Y. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00166
Programming the immunological properties of mRNA vaccines for cancer
Wu, A., Jeong, S. D., Schrank, B. R., Kim, B. Y. S., Sharma, P., & Jiang, W. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01316-z · Cited by 1
Cytokine-mediated mechanisms of TAM in driving cancer progression
Jamali, M. C., Al-Samawi, R. I., Patel, A. A., Mekkey, S. M., Mallick, A. K., Dawood, S. A., Sadikan, M. Z., Mustafa, A. E. M., Mansuri, N., Qureshi, M. A., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117125 · Cited by 1
Ma, J., Chen, J., Miao, T., Li, Y., Li, Y., Zhao, L., & Tian, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08711-z
Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer
Fernández-Luna, C., Baena-, J., Calles, A., Antoñanzas, M., Lage, Y., Mielgo-Rubio, X., Sereno-Moyano, M., Cervera, R., Cabezón‐Gutiérrez, L., López, A., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-016133
Nonviral nucleic acid delivery systems: specific features of polymeric carriers
Shaputkin, E. D., Nifant'ev, I. E., & Ivchenko, P. V. (2026) · Russian Chemical Reviews · doi:10.59761/rcr5222
Rehman, A. U., Khan, M. A.-U.-R., Akhtar, A., Qin, Q., Zhang, X. X., Asghar, M. A., Ling, D., Wang, P., Luo, Y., Wang, Z., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-017160
Metadata
- Authors
- Haabeth, O. A. W., Blake, T. R., McKinlay, C. J., Tveita, A. A., Sallets, A., Waymouth, R. M., Wender, P. A., & Levy, R.
- Affiliations
- Oslo University Hospital (NO)
- Stanford University (US)
- Stanford Medicine (US)
- Corresponding author
- Levy, Ronald
- ORCID
- Venue
- Cancer Research
- Published
- 2019-04-01
- Volume
- 79
- Issue
- 7
- Pages
- 1624-1634
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC6445668
- OpenAlex
- W2911764398
- Cited by
- 129
- References
- 48
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 18 · 2023: 21 · 2022: 20 · 2021: 22 · 2020: 12 · 2019: 8
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Funders
- HHS | National Institutes of HealthHHS | National Institutes of Health (NIH) (R35CA197353, NIH-CA031845)
- National Science FoundationNational Science Foundation (NSF) (NSF CHE-1607092, NSF CHE-848280)
- KreftforeningenKreftforeningen (Norwegian Cancer Society) (6918722)
- National Cancer CenterNational Cancer Center (T32 CA196585)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- systemic antitumor immunity, OX40L, CD80, CD86, costimulatory molecules, tumor microenvironment, tumor-infiltrating dendritic cells, tumor-infiltrating macrophages, T cell activation, draining lymph nodes, inflammatory cytokines
- MeSH terms
- Animals, Female, Membrane Glycoproteins, Mice, Inbred BALB C, Neoplasms, RNA, Messenger, B7-1 Antigen, Tumor Necrosis Factors, Mice, B7-2 Antigen, OX40 Ligand, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
